Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Purchases $57,240.00 in Stock

Greenwich LifeSciences, Inc. (NASDAQ:GLSIGet Free Report) CEO Snehal Patel acquired 3,000 shares of the stock in a transaction on Monday, April 1st. The shares were bought at an average cost of $19.08 per share, for a total transaction of $57,240.00. Following the purchase, the chief executive officer now directly owns 5,350,777 shares of the company’s stock, valued at approximately $102,092,825.16. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website.

Snehal Patel also recently made the following trade(s):

  • On Friday, March 22nd, Snehal Patel acquired 2,500 shares of Greenwich LifeSciences stock. The shares were bought at an average cost of $19.98 per share, for a total transaction of $49,950.00.
  • On Wednesday, March 20th, Snehal Patel acquired 1,500 shares of Greenwich LifeSciences stock. The shares were bought at an average cost of $17.68 per share, for a total transaction of $26,520.00.
  • On Monday, March 4th, Snehal Patel acquired 4,100 shares of Greenwich LifeSciences stock. The shares were bought at an average cost of $13.03 per share, for a total transaction of $53,423.00.
  • On Thursday, February 15th, Snehal Patel bought 12,700 shares of Greenwich LifeSciences stock. The stock was acquired at an average price of $11.07 per share, for a total transaction of $140,589.00.

Greenwich LifeSciences Stock Performance

NASDAQ:GLSI opened at $17.49 on Wednesday. Greenwich LifeSciences, Inc. has a 52 week low of $7.58 and a 52 week high of $21.44. The stock’s fifty day moving average is $13.52 and its two-hundred day moving average is $11.14.

Institutional Investors Weigh In On Greenwich LifeSciences

Several institutional investors and hedge funds have recently modified their holdings of GLSI. Vanguard Group Inc. raised its holdings in shares of Greenwich LifeSciences by 150.2% in the 1st quarter. Vanguard Group Inc. now owns 375,200 shares of the company’s stock valued at $7,362,000 after buying an additional 225,213 shares during the period. State Street Corp raised its holdings in shares of Greenwich LifeSciences by 1.8% in the 1st quarter. State Street Corp now owns 66,485 shares of the company’s stock valued at $1,304,000 after buying an additional 1,176 shares during the period. Bank of America Corp DE raised its holdings in shares of Greenwich LifeSciences by 100.2% in the 1st quarter. Bank of America Corp DE now owns 6,213 shares of the company’s stock valued at $122,000 after buying an additional 3,110 shares during the period. Renaissance Technologies LLC purchased a new stake in shares of Greenwich LifeSciences in the 2nd quarter valued at $891,000. Finally, Millennium Management LLC purchased a new stake in shares of Greenwich LifeSciences in the 2nd quarter valued at $765,000. Hedge funds and other institutional investors own 4.16% of the company’s stock.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and issued a $36.00 target price on shares of Greenwich LifeSciences in a research report on Wednesday, February 28th.

View Our Latest Report on Greenwich LifeSciences

About Greenwich LifeSciences

(Get Free Report)

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.

Read More

Insider Buying and Selling by Quarter for Greenwich LifeSciences (NASDAQ:GLSI)

Receive News & Ratings for Greenwich LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Greenwich LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.